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Abstract
Stem cells contribute to regeneration of tissues and organs. Cells with stem cell-like properties have been identified in
tumors from a variety of origins, but to our knowledge there are yet no reports on tumor-related stem cells in the human
upper respiratory tract. In the present study, we show that a tracheal mucoepidermoid tumor biopsy obtained from a 6
year-old patient contained a subpopulation of cells with morphology, clonogenicity and surface markers that overlapped
with bone marrow mesenchymal stromal cells (BM-MSCs). These cells, designated as MEi (mesenchymal stem cell-like
mucoepidermoid tumor) cells, could be differentiated towards mesenchymal lineages both with and without induction, and
formed spheroids in vitro. The MEi cells shared several multipotent characteristics with BM-MSCs. However, they displayed
differences to BM-MSCs in growth kinectics and gene expression profiles relating to cancer pathways and tube
development. Despite this, the MEi cells did not possess in vivo tumor-initiating capacity, as proven by the absence of
growth in situ after localized injection in immunocompromised mice. Our results provide an initial characterization of
benign tracheal cancer-derived niche cells. We believe that this report could be of importance to further understand
tracheal cancer initiation and progression as well as therapeutic development.
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Introduction
Primary tracheal tumors are very rare, representing only up to
0.2% of all respiratory malignancies [1–3]. This is particularly true
in the paediatric population. The most common tracheal
neoplasm reported in children is mucoepidermoid carcinoma, a
salivary gland-type cancer [4,5]. The mucoepidermoid tumors are
histologically heterogenous low-grade tumors that grow locally,
without metastasis [3,6,7]. It is usually identified by a characteristic
translocation/fusion transcript at t(11;19) [8]. Due to their rarity,
the characteristics and biology of these neoplasms remain poorly
understood. However, it has been proposed that tracheal tumors
may originate from niche cells that reside in the respiratory
epithelium, glands or mesenchymal niches. These could be either
a population of tissue stem cells, transformed progenitor cells or
cancer stem cells (CSCs) [9–11].
Normal stem cells and tumorigenic cells share many resem-
blances with regard to gene expression profiles, morphology and
both have extensive proliferative potential with the ability to give
rise to new (normal or abnormal) tissues [12–14]. The growth of
solid cancers has been suggested to be driven by what has been
generally termed ‘cancer stem cells’ (CSCs), reported from
malignant tumors of various tissues such as lung [15–18], pancreas
[19–21], prostate [22–25], colon [26] and breast [27]. Normal
stem cells and CSCs show also similarities with regard to their
dependencies on sonic hedgehog (Shh) [28,29], Notch [9] and
Wnt [30,31] pathways.
A presence of stem-like cells detected in also benign tumors, as
shown in the present paper, is in accordance with a previous
report by Xu and colleagues studying pituitary adenoma [32].
However, stem cells have so far not been demonstrated in
transformed tissues from the human upper respiratory tract. We
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here identified and characterized the expanded primary cultures
from a benign paediatric mucoepidermoid tracheal tumor.
Materials and Methods
Ethics statement
Animal experiments. Animal experimentation was per-
formed according to ethical permission numbers N173/10 (Stock-
holm Northern Animal Review Board) and S180/12 (Stockholm
South Ethical Committee). All animals were treated in compliance
with the ‘‘Principles of laboratory animal care’’ formulated by the
National Society for Medical Research and the ‘‘Guide for the
care and use of laboratory animals’’ prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. All
surgery was performed under anesthesia, and all efforts were made
to minimize animal pain and suffering.
Patient sample. The Stockholm Regional Ethical Review
Board has approved the study to collect patient material according
to ethical permission numbers 2008 307-31 and 2012 2163-311
with written informed parent’s consent to publish. All clinical
research was conducted according to the principles expressed in
the Declaration of Helsinki. A tracheal sample was obtained from
a 6-year-old female patient. She was surgically treated for a
diagnosis of primary mucoepidermoid tumor, and underwent
subtotal tracheotomy at Karolinska University Hospital, Stock-
holm, Sweden. Half of the tissue was fixed and paraffin-embedded
for pathological analyses, and half processed for cellular and
molecular analyses.
Tracheal patient pathology
The tissue was fixed, paraffin-embedded and sectioned at 5 mm,
de-paraffinized and stained for the following: Haematoxylin Eosin
(HE) (Histolab, Sweden), periodic acid-Schiff stain (DAKO,
Denmark), Ki67 (DAKO), Muc-1 (BD Biosciences, CA, USA),
cytokeratin markers (Ck) MNF116 (DAKO), carcino-embryonic
antigen (CEA) (DAKO) and androgen receptor (Ventana,
Switzerland). Three pathologists determined the proliferation
index independently by manually counting the number of
proliferative cells present in 10 fields at 406magnification. Total
RNA was purified from paraffin sections with a QIAamp RNeasy
Kit and was processed according to manufacturer’s instructions
(Qiagen, Germany). cDNA was obtained with a high-capacity
cDNA reverse transcription kit (Applied Biosystems, CA, USA).
The samples were run on 7000 Fast Real-Time PCR System
(Applied Biosystems) in duplicates with TaqMan probes for
detection of fusion transcripts.
Isolation, expansion and maintenance of trachea tumor
cells
Tumor tissue was manually minced with a scalpel followed by
enzymatic digestion at 37uC; 5% CO2 for 1.5 hours in 24 U/ml
Dispase and 1% Collagenase Type 1a (all from Invitrogen, Life
Technologies, Sweden) in Hank’s Balanced Salt Solution. The
collagenase activity was discontinued on ice and the cell
suspension was then strained with a 70 mm cell strainer (BD
Biosciences, Sweden), centrifuged for 6 minutes at 600 g and
finally seeded into a 75 cm2 flask with tracheal culture medium
(see below). Fifty percent of the culture medium was changed after
4 days and subsequently the medium was changed completely
every three days. When cells reached 90% confluence, cells were
trypsinized for 5 minutes at 37uC with TryPLe Select (Invitrogen,
Life Technologies), collected and centrifuged for 5 minutes at
300 g and cell pellet was subcultured at a 1:3 ratio.
Culture medium of tracheal tumor cells
Cells were cultured and expanded in Dulbecco’s modified
Eagle’s medium with low glucose (DMEM), 10% fetal bovine
serum (FBS) and 1% antibiotics (penicillin/streptomycin) and
antimycotics (amphotericin B) (all from Invitrogen, Life Technol-
ogies).
Cell sorting trachea tumor cells by FACS
Trachea cells at passage 12 were trypsinized and resuspended in
FACS (Fluorescence Activated Cell Sorting) buffer (Dulbecco
Phosphate buffered solution without calcium and magnesium, 2%
Fetal Bovine Serum and 1 mM EDTA) and strained through a
70 mm cell strainer to avoid aggregates. Single cells suspensions
were incubated with previously titrated antibody mix: CD105,
CD90, CD73, CD44, CD31, CD45, CD34, CD11b, HLA-DR
and CD14 (all from BD Biosciences) and incubated for 20 minutes
at room temperature. After washing, the cells were resuspended in
FACS buffer at a concentration of 206106/ml. Cells were sorted
with an Aria III (BD Biosciences) equipped with 405 nm, 488 nm,
561 nm and 633 nm lasers. Cells were recovered and grown to
confluence in DMEM, 20% FBS and 1% antibiotics (penicillin/
streptomycin). The post-sorted mucoepidermoid tumor cells will
hereafter be referred as MEi (MSC-like mucoepidermoid tumor)
cells, p9+1 and p12+1. MEi cells from passages p9+2 to p9+6,
p12+2 to p12+6 are used in this study.
FACS isolation and analysis of human BM-MSCs
Human BM-MSCs were sorted, expanded to passage 6 and
used as a positive control. BM-MSCs were isolated by multi-color
FACS as described previously [33]. Briefly, mononuclear cells
from BM aspirates of healthy adult volunteers were isolated by
Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS, Norway)
density centrifugation. The CD452CD2352 cells were enriched
by negative selection using CD45 and CD235 microbeads and
magnetic-activated cell sorting (MACS, Miltenyi Biotec, Ger-
many). The cells were stained with anti-human CD271 (Biolegend,
CA, USA), CD146 (Biolegend), CD452 and Glycophorin A/
CD235 (eBioscience, CA, USA). Dead cells were excluded by
propidium iodide staining (Sigma-Aldrich, Sweden). The CD44+
MSCs were sorted on FACSAria II Sorp (BD Biosciences).
Immunocytochemistry staining
Lineage tracing markers were used to determine tracheal
mucoepidermoid tumor origin at passage 3. To further determine
the differentiation potential of MEi (MSC-like mucoepidermoid
tumor) cells in comparison to BM-MSCs, cells were induced and
stained for endoderm and ectoderm lineage markers. Cells were
fixed with 4% formalin (Histolab) at room temperature for
10 minutes and were washed three times. Cells were blocked with
5% FBS (Invitrogen, Life Technologies) and 0.1% Triton X
(Sigma-Aldrich) in DPBS for 1 hour at room temperature on a
rocking platform. The cells were stained with primary antibodies
on a rocking platform overnight at 4uC. Trachea tumor cells
before and after sorting were stained with mouse monoclonal to
MUC 1 (1:50) (ab70475, Abcam, UK) and rabbit polyclonal to
MAML2 (1:50) (ab90592, Abcam). The cells were washed with
DPBS with 0.1% Tween 20 (Sigma-Aldrich). The corresponding
secondary antibodies, Alexa 488 goat anti rabbit (1:2000) (A11008,
Life technologies), and Alexa 594 goat anti mouse (1:2000)
(A11032, Life technologies) were incubated on a rocking platform
at room temperature for 1 hour.
MEi cells were stained with primary antibodies overnight at 4uC
for endoderm; rabbit monoclonal to GATA6 (1:1600) (#5851,
Stem Cells in Primary Tracheal Tumors
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Cell Signaling) and ectoderm; rabbit monoclonal to b III tubulin
(1:100) (#5568, Cell Signaling, USA) markers. Cells were washed
with DPBS with 0.1% Tween 20 (Sigma-Aldrich). The corre-
sponding secondary antibody, Alexa 488 goat anti rabbit (1:500)
(A11008, Life technologies) was incubated on a rocking platform
at room temperature for 1 hour. After secondary antibody
application, cells were washed with DPBS with 0.1% Tween 20
and were counterstained with SlowFade Gold antifade mountant
with nuclear marker 49,6-diamidino-2-phenylindole (DAPI) (Mo-
lecular Probes, Life Technologies). Cells were visualized and
imaged under an inverted microscope (Olympus IX70, Japan).
Negative controls for each secondary antibody were performed
without the addition of primary antibody, and no non-specific
binding was detected. The number of positive MUC 1 and
MAML2 and DAPI stained cells was quantified by manually
counting in 3 fields at 620 magnification. Results are presented in
percentages.
Mathematical modeling of in vitro growth of trachea
tumor cells
A mathematical modeling was designed to calculate the
doubling times of cells, and to estimate the number of MEi
(MSC-like mucoepidermoid tumor) cells as a proportion of the
total number of adherent cells from the original tumor tissue.
Estimation of cell doubling times. Unsorted tumor cells,
MEi cells and BM-MSCs were initially seeded in triplicates at cell
densities of 103/0.32 cm2. Dead cells were identified by trypan
blue (Sigma-Aldrich) and were manually counted in triplicates
with a Bürker counting chamber (Marienfeld, Germany). The
estimates of the doubling times were calculated by assuming
exponential growth in cell numbers, hence N(t) = N0 exp (kt) (1)
where N is the number of cells in culture after a time t, and N0 and
k are regression parameters corresponding respectively to the
number of cells in the culture at t = 0 and the cell proliferation
rate. Using least squares minimization, equation (1) was fitted to
time courses of the cell numbers from each well, giving a total of 9
pairs of values of N0 and k. The mean proliferation rates for
unsorted tumor cells, MEi cells, and BM-MSCs were found to be
k = 0.2243, 0.2502, and 20.0182 day21 respectively. Using the
fitted value of k for each corresponding well, the doubling times
were calculated using t= ln 2/k. The mean and uncorrected
standard deviations of doubling times were found to be
t= 3.360.8 days for unsorted tumor cells, t= 2.860.4 days for
MEi cells, and t= 636132 days for BM-MSCs.
Estimation of the proportion of MEi (MSC-like
mucoepidermoid tumor) cells that reside at tumor
tissue. It was found that after t = 21 days (3 weeks) of culturing
the adherent cells from the tumor tissue, there were a total of
3.256106 cells and, of the 36106 cells that were analyzed, there
were 903.76103 MEi cells. Therefore, the total number of MEi
cells at the end of the culture period was 903.7610363.25/
3<9796103.
To calculate the number of cells at the initial of the culture
(passage 0), equation (1) was rearranged to give N0 in terms of N, k
and t: N0 = N exp (-kt). (2) For unsorted tumor cells, applying
equation (2) with N = 3.256106, k = 0.224 and t = 21 gave
N0 = 29.2610
3 as the number of cells that were present at the
initial culture period. For MEi cells, applying (2) with
N = 9796103, k = 0.250 and t = 21 gave N0 = 5.1610
3 as the
number of cells that were present at the beginning of the culture.
Hence the proportion of adherent cells that were MEi cells in the
tumour tissue was estimated to be 17.5%.
Colony forming fibroblast (CFU-F) assay
MEi (MSC-like mucoepidermoid tumor) cells and BM-MSCs
were cultured for 13 days in vitro at a cell density of 104/9.60 cm2.
Cells were fixed for 10 min at room temperature in 4% formalin
(Histolab). Cells were washed three times and 0.06% Giemsa
staining (Sigma-Aldrich) was incubated for 5 minutes at room
temperature. The staining was gently rinsed with distilled water
and air-dried. A colony was defined as a stained cluster of
approximately $50 cells. The colonies were quantified under
brightfield microscopy (Olympus IX70, Japan).
Suspension cultures for production of spheroids
MEi cells were trypsinized and either seeded onto ultra-low
attachment surfaces (Corning, NY, USA) in culture media at a cell
density of 26105/cm2 or alternatively placed in hanging drop
cultures of 15 to 20 cells per drop on the lid of a Petri dish (BD
Biosciences) in a static culture condition. The suspension culture
media was refreshed every third day and the hanging drops were
topped up with more culture media every third day.
Spheroid culture medium
Dulbecco’s modified Eagle’s medium, low glucose was supple-
mented with 20% fetal bovine serum (FBS), 16penicillin-
streptomycin, 16GlutaMAX and 16non-essential amino acid
solution and 0.5 mM 2-mercaptoethanol (all from Invitrogen, Life
Technologies).
Directed and spontaneous differentiation and evaluation
of spheroid and monolayer cultures
Day 10 spheroids from MEi cells were transferred from ultra
low attachment suspension culture and plated onto non-coated BD
Falcon center-well IVF dish (BD Biosciences). The spheroid
outgrowths were either differentiated under two conditions: with
or without differentiation media. The outgrowths were directly
differentiated with STEMPRO osteogenic, adipogenic and chon-
drogenic differentiation kits (Invitrogen, Life Technologies) and
analyzed at day 12 and 24. The outgrowths (both directed and
spontaneous differentiation) were stained with Toluidine Blue,
Alizarin Red and Oil Red, respectively (all Sigma-Aldrich, MO,
USA) to confirm mesenchymal trilineage differentiation. Out-
growths without differentiation media were further confirmed by
flow cytometry at day 25 for a panel of mesenchymal stromal cell
markers.
Monolayer cultures from MEi cells and BM-MSC were seeded
for 48 hours at a cell density of 103 cells in 4 well BD Falcon
CultureSlides (BD Biosciences) and were induced for 7 days with
100 ng/ml BMP4 (endoderm) (R&D systems, Sweden) or 100 ng/
ml Retinoic acid (mesoderm) (Sigma-Aldrich). Cell culture media
was refreshed every second day [34].
Total RNA extraction from cells
Total RNA was isolated from the freshly isolated and cultured
human cells using a commercially available RNeasy Mini Kit
(Qiagen). RNA extraction was processed according to the
manufacturer’s instructions.
MicroRNA isolation and purification from cells
MicroRNA from BM-MSCs, unsorted tumor cells, sorted (MEi
cells) and spontaneously differentiated spheroid outgrowths were
isolated by phenol/chloroform method. Briefly, 800 mL phenol
(Qiazol, Sweden) and 200 mL chloroform were added and mixed
vigorously for 15 seconds followed by incubation at room
temperature for 10 minutes. The samples were centrifuged for
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30 minutes at 12,000 g until complete phase separation. The
aqueous phase (with total RNA) was precipitated with 500 mL
100% isopropanol and 2 mL glycogen (Fermentas, Germany)
overnight at 220uC. Samples were centrifuged at 4uC for
15 minutes at 12,000 g and obtained pellets were washed once
with 70% ethanol. The precipitated RNA was re-suspended in
30 mL RNase free water (Ambion, Austin, TX). RNA quantity and
quality was assessed using a NanoDrop spectrophotometer
(NanoDrop, Wilmington, DE, USA) and a smallRNA assay for
Agilent’s Bioanalyzer (Agilent Technologies, Germany).
cDNA preparation
The Affymetrix Gene Chip WT Sense Target Labeling and
Control Reagents kit was used for preparation of cDNA from
100 ng of total RNA according to the manufacturer’s protocol.
Briefly, total RNA was first reverse transcribed using a T7-Oligo
(dT) Promoter Primer in the first-strand cDNA synthesis
reaction. Following RNase H-mediated second-strand cDNA
synthesis, the double-stranded cDNA served as a template in the
subsequent in vitro transcription (IVT) reaction carried out in
the presence of T7 RNA Polymerase. cRNA was purified using
the Nucleic Acid Binding Beads and quantified by UV
absorbance at 260 nm on the ND1000 spectrophotometer
(Thermo Scientific, MA, USA). Sense strand cDNA was
synthesized by the reverse transcription of 10 mg of cRNA
using random primers. The cRNA template was hydrolyzed
using RNase H and single stranded cDNA purified and
quantified using the same methods described above.
Microarray hybridization
cDNA was fragmented and labeled using the GeneChip WT
Terminal Labeling Kit. The Affymetrix Gene Chip Human
Gene 1.1 ST Array plates were used for hybridization. Array
hybridization was done at 45uC, 60 rpm for 17 hours. Chips
were washed, stained and scanned on a Gene Titan Instrument
according to the manufacturer’s recommendations.
Microarray data analysis
Signal intensities from raw CEL files were extracted, normalized
and summarized by using the robust multi-array average (RMA)
function implemented in the R Bioconductor software. Affymetrix
control probe and probe sets with little variations across samples
and no Entrez Gene identifiers were filtered out. Filtered probe
sets were used to group samples by Principal Component Analysis
(PCA) and the top 100 probe sets with the highest interquartile
range were used to group the samples by hierarchical clustering.
To identify genes that were significantly different between the
tumor cells and BM-MSC, a modified t-test incorporating the
Benjamini-Hochberg multiple hypotheses correction technique
was used [35]. A total of 454 differentially expressed genes with
fold change greater than 4 were processed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
Gene Annotation Tool [36] to identify biological differences
between the two cell types. Microarray data are available in the
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under ac-
cession number E-MTAB-2093
Karyotype analysis
Slides for metaphase G-banding were prepared using
standard techniques. Cells were treated with 0.1 mg/ml
Colcemid (Invitrogen, Life Technologies) for up to 4 hours,
followed by dissociation with trypsin/versene. The cells were
pelleted via centrifugation and resuspended in pre-warmed
0.0375 M KCl hypotonic solution and incubated for 10 min-
utes. Following centrifugation the cells were resuspended in
fixative (3:1 methanol:acetic acid). One drop of suspension was
dropped onto a glass microscope slide (Sigma-Aldrich).
G-banding
G-banding was performed by exposure to trypsin for
25 seconds and stained with 4:1 Gurr’s/Leishmann’s stain
(Sigma-Aldrich) for 2 minutes. G-banded slides were scanned,
metaphases captured and analysed using a Cytovision GSL-120
(Leica Microsystems, Switzerland) image analysis system. A
minimum of 5 metaphase spreads were analyzed and a further
45 counted and scored. A health professional council registered
Clinical Scientist in Clinical Pathology Accredited laboratory
performed the analyses.
Molecular karyotyping
For Array Comparative Genomic analysis, an 180 K
oligonucleotide microarray with even whole genome coverage
and median probe spacing of approximately 16 kb was used
(Oxford Gene Technology, UK). Genomic DNA isolated from
the cells of primary tracheal tumor patient and a sex-matched
pooled reference DNA isolated from healthy controls (Promega,
WI, USA) were labeled with Cy3 and Cy5 respectively (Enzo
Life Sciences, NY, USA). Hybridization and slide washing
(Oligo aCGH/ChIP-on-Chip Wash Buffer Kit, Agilent Tech-
nologies, DE, USA) were performed according to the manufac-
turers’ recommendations. Scanning of the array slide was
performed on a microarray scanner with 3 mm resolution and
initial data analysis was performed with the Feature Extraction
software v 10.7.3.1 (Agilent Technologies) followed by analysis
with the CytoSure Interpret Software v 4.3 (Oxford Gene
Technology).
Analysis of in vivo growth
Trachea tumor cells sorted for MSC markers were either
injected as dissociated cells (16106/mouse) or as day 10
spheroids (20/mouse). Cells were injected into 6 to 8 weeks
old male SCID/Beige mice (C.B.-17/GbmsTac-scid-bgDF N7;
M&B; C.B-17/scid-beige, Taconic) either under the testes
capsule (n = 6) or subcutaneously (n = 5). In the group with
subcutaneous injection, growth factor reduced Matrigel (BD
Biosciences) was used as vehicle. The animals were euthanized
at 8 weeks after inoculation. For the microscopic analysis, testis
and fibrous/fat tissue at the site of subcutaneous injections were
excised and fixed overnight at 4uC in 4% paraformaldehyde
(Histolab), dehydrated through a graded series of alcohol to
xylene, embedded in paraffin, and serially sectioned at 5 mm
thickness.
Sections were subjected to standard HE staining for basic
histological orientation. For the identification of human cells,
Fluorescent In Situ Hybridization (FISH) was performed using a
mixed probe against the human X-chromosome (red) and Y-
chromosome (green) (CEP XY; Vysis Inc, IL, USA), as previously
described [37].
Statistical analysis
Data analyses were performed using Student t-tests and
preparation of graphs, and statistical comparisons were undertak-
en with Prism software (GraphPad Prism version 5.0, MAC
version). Statistical significance was accepted at p,0.05.
Stem Cells in Primary Tracheal Tumors
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Results
Pathological evaluation was consistent with a diagnosis
of mucoepidermoid cancer
A primary tracheal subocclusive mucoepidermoid tumor
specimen was obtained from a 6-year-old girl who underwent
segmental tracheal resection and primary surgical reconstruction.
The excised part of the trachea measured 1.4 cm in length and
1.5 cm in width. In the lumen, a 1.3 by 1.2 by 0.9 cm polypous
tumor was present. The resection margins of the tumor were inked
before gross examination. Transversal sections from cranial to
caudal parts were made and subsequent Haematoxylin Eosin (HE)
staining revealed a polypoid tumor partly covered with respiratory
mucosa (Figure 1a). Evaluations after periodic acid-Schiff staining
and immunohistochemical labeling with antibodies against Muc-1
showed that the tumor was solid with trabecular/insular growth
patterns and cystic with mucus-secreting cells (Figure 1b and c).
Further, there were foci with squamous differentiation without
atypia in desmoplastic stroma with psammoma calcifications. The
tumor was confined to the mucosa and submucosa with no signs of
expansion into the tracheal cartilage. No necrotic areas or marks
of vascular/perineural invasion were detected, but various degrees
of chronic inflammation were noted in the tracheal mucosa. In
addition, antibodies against the cytokeratin marker Ck-MNF116
stained epithelial cells (Figure 1d), as did antibodies against
carcino-embryonic antigen (CEA) (Figure 1e). Androgen receptor
(AR) labeling was negative (Figure 1f). The stromal component in
the tumor cells was negative for smooth muscle actin (SMA)
(Figure 1g). Immunostaining with the cell proliferation marker
Ki67 demonstrated that few mitoses were present. The tumor cells
had a proliferation index of 5% on average, with a few hot spots
reaching a proliferation index of up to 10% (Figure 1h). With
PCR-analysis, we identified positive fusion transcript CRTC1-
MAML2, which is associated with translocation t(11;19) (q21;p13)
[8,38]. Taken together, and due to the rarity of the diagnosis, there
are different ways to classify the grade of the tumor. According to
the NCCN guidelines for mucoepidermoid tumors, the patient
presented a low-grade tumor classification of T1N0M0. This is
also compatible with a tumor diagnosis of low (according to AFIP/
Auclair) [39] and intermediary (according to Brandwein) grade
[40].
Isolation and expansion of mucoepidermoid tumor cells
sorted for MSC markers
For cell culture, tumor tissue was homogenized and seeded as
described in Materials and Methods. Monolayer cultures yielded
cells with spindle-shaped fibroblast-like appearances, closely
resembling bone marrow-derived mesenchymal stromal cells
(BM-MSCs) (Figure 2a and b). Mucoepidermoid tumors arise
from the serous and mucous glands of the upper airway and
salivary glands. With a possibility that the tumor cells originate
from mesenchymal stromal cells, we aimed to investigate
differences and similarities between tracheal tumor cells and
BM-MSCs. To characterize the expanded mucoepidermoid tumor
cells, we confirmed the tumor lineage trace by MUC 1 and
MAML2 expression before (passage 3; Figure 2c and d) and after
(passage 12+5; Figure 2 h and i) cell sort. We found the majority of
cells expressed MUC 1 and MAML2 (89% and 95% respectively).
By fluorescence-activated cell sorting (FACS) analyses, we detected
a nearly homogenous phenotype displaying typical MSC charac-
teristics: 98% strongly expressed CD44, CD73, CD90 and
CD105, and were negative for haematopoietic markers CD11b,
CD14, CD34, CD45 (Figure 2e). The post-sorted mucoepider-
moid tumor cells maintained their morphology throughout the
expansion process up to passage 12+6 and will hereafter be
designated as MEi (MSC-like mucoepidermoid tumor) cells
(Figure 2f and g). We noted that the doubling time of unsorted
tumor cells (3.360.8 days) and MEi cells (2.860.4 days) were
considerably faster than BM-MSCs (636132 days). Using an
unpaired t-test, we determined that there was no significant
difference between the proliferation rates of unsorted tumor cells
and MEi cells (see experimental procedures). Clonogenic assay
also demonstrated that MEi cells (123638.97) contained more
CFU-F colonies in all triplicates when compared to BM-MSCs
(53.3362.52).
In vitro differentiation of MSC-like mucoepidermoid
tumor (MEi) cells
Following trypsinization of MEi cells from passages 9+1, 12+2
and 12+6, we evaluated cell stemness by sphere formation and
differentiation [41]. Spheroid bodies formed at an efficiency rate
close to 100% in suspension cultures or in hanging drops under
Figure 1. Histological and pathological analyses of a mucoepidermoid tumor. Haematoxylin and Eosin staining provides visualization of
the excised tracheal mucoepidermoid tumor biopsy (a), periodic acid-Schiff stain identifies mucins and glycoproteins in magenta (b), Mucin 1, Muc-1
identifies mucin-producing cells (c), Cytokeratin marker, Ck-MNF116 shows epithelial staining (d), carcino-embryonic antigen, CEA is an oncofetal
antigen expressed by some tumors but not in normal adult tissues (e), androgen receptor, AR is a predictive marker for choice of therapy (f), muscle
specific actin, MSA identifies the stromal component (g), and Ki-67 is a cell proliferation marker used for quantifying the proliferative index of the
tumor (h). Scale bar: 100 mm.
doi:10.1371/journal.pone.0107712.g001
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static culture conditions. Spheroids were compact by day 10 of
culture, and had diameters ranging between 100 and 125 mm with
a circumferential outer layer of endodermal-like cells (Figure 3a).
When plated on organ culture tissue plates such spheroid bodies’
outgrowths could be further cultured for up to 1 month (Figure 3b
and c). However, after 25 days, 99.9% of 10,000 counted cells had
retained a pronounced mesenchymal stromal cell morphology and
immuno-phenotype, which may typically be the long-term
dormant cells (Figure 3d–g). To investigate their differentiation
capacity, passage 12+3 MEi cells were cultured in three types of
defined growth factor-enriched medium (see experimental proce-
dures). In each appropriate medium, 80% of cells differentiated
either towards osteoblast (Alizarin R staining; Figure 4a), adipo-
cyte (Oil red staining; Figure 4b) or chondrocyte lineages
(Toluidine blue staining; Figure 4c). To study spontaneous
differentiation, cells were grown in standard culture media devoid
of growth factor enrichment. We found that approximately 10% of
the cells spontaneously differentiated towards the three phenotypes
i.e. osteoblast, adipocyte and chondrocyte (Figure 4d–f). Although
the in vitro differentiation potential evaluations proved that MEi
cells are multipotent, microRNA biomarkers miR 34/449 family
was observed to be differentially expressed in the tracheal tumor
cells when compared to the BM-MSCs (Figure 4g). We further
explored the differentiation potential of MEi cells to both
endoderm and ectoderm lineages in comparison to BM-MSCs
(Figure 5). We observed that a subpopulation of MEi cells were
positive for GATA6 (Figure 5a–c) and b-III tubulin (Figure 5g–i)
(51% and 12.5% respectively) were similar to BM-MSC (Figure 5
d–f, j–l)
Differences in gene expression profiles between MEi cells
and BM-MSCs
To investigate potential differences between MEi cells and BM-
MSCs, we assessed their respective gene expression profiles using
microarray analysis. When examined with Principal Components
Analysis (Figure 6a) as well as through hierarchical clustering
Figure 2. Cell morphology, lineage tracing, FACS sort and proliferation rates of mucoepidermoid tumor before and after sorting.
Mucoepidermoid tumor cells at passage 0, Scale bar: 100 mm (a), BM-MSCs at passage 6, Scale bar: 100 mm (b), a representation of the merged images
of MUC 1 and MAML2 before, Scale bar: 20 mm (c, d) and after, Scale bar: 50 mm (h, i) sort, flow cytometry sorting for a panel of mesenchymal stromal
cell markers (e), post-sorting of MEi cells after 24 hours recovery, Scale bar: 500 mm (f) and a representative image of expanded post-sorted p12+5 MEi
cells, Scale bar: 500 mm (g), cell proliferation rates and doubling times of unsorted and sorted cells (black and red respectively) versus BM-MSC (blue)
(j). Colored circle indicates the raw datasets for the number of cells in each well; crosses and error bars indicate means and standard deviations.
doi:10.1371/journal.pone.0107712.g002
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(Figure 6b), MEi cells and BM-MSCs formed distinct constella-
tions that were clearly separated from each other. These results
indicate that the MEi cells are different from the BM-MSCs based
on their gene expression profile patterns. Using unpaired t-test, we
found that a total of 1900 genes were significantly different
between MEi cells and BM-MSCs (p,0.02). The MEi cells were
found to not display gene expression profiles that were associated
Figure 3. Spheroid cultures and flow cytometry analyses of spheroid outgrowths. Day 10 spheroids in low adhesion culture plates (a), day
10 trachea spheroids plated onto culture plates after 24 hours (b), outgrowths from spheroid cultures (c). Flow cytometry analyses of spheroid
outgrowths after 25 days in vitro. Scale bar: 100 mm. Cell morphology before (d) and after (f) trypsinization. Scale bar: 200 mm. Flow cytometry
analyses for a panel of mesenchymal stromal cell markers before (e) and after (g) trypsinization.
doi:10.1371/journal.pone.0107712.g003
Figure 4. Differentiation of MEi (MSC-like mucoepidermoid tumor) cells to mesenchymal trilineage. Directed differentiation with
growth factors (a–c): towards osteoblast phenotype (alizarin Red staining) (a), towards adipocyte phenotype (Oil red staining) (b), towards
chondrocyte phenotype (toluidine blue staining) (c); Spontaneous differentiation without growth factor (d–f). alizarin S staining (d) oil red staining (e),
toluidine blue staining (f). Scale bars: 100 mm. MicroRNA analyses of miR-34, miR 449a, b, c for BM-MSC, unsorted, sorted and spontaneous
differentiation of tracheal tumor cells (g).
doi:10.1371/journal.pone.0107712.g004
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with normal stem or tumorigenic cells such as SOX2, OCT4, C-
MYC.
To further understand the biological differences between MEi
cells and BM-MSCs, enrichment analysis using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
Gene Functional Classification Tool was performed using the
differentially expressed genes as input. From the full list of
pathways in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database, pathways in cancer, purine metabolism and
ECM receptor interactions were found to significantly enriched by
the differentially expressed genes (Table 1). Thus, it is likely that
these pathways contribute to the functional differences that were
observed between MEi cells and BM-MSCs. For the KEGG
annotation ‘Pathways in cancer’, a partial list of the differentially
expressed genes most relevant to this pathway is provided in
Table 2. Interestingly, genes that have been previously found to be
overexpressed in other cancers such as hepatocyte growth factor
(HGF), laminin alpha 4 (LAMA4) and androgen receptor (AR)
were also found to be more highly expressed in MEi cells
compared to BM-MSCs.
Functional Annotation Clustering groups all the Gene Ontology
(GO) terms that are significantly enriched in order to reduce
redundancy, as many of the GO terms are similar. When the
Functional Annotation Clustering of GO terms was performed
using the differentially expressed genes as input, several interesting
clusters with high enrichment scores were obtained. These clusters
represent those that are related to tube development, cell
adhesion, angiogenesis, signal transduction, inflammatory re-
sponse and regulation of programmed cell death, suggesting that
these areas contribute to the differences observed between MEi
cells and BM-MSCs. A partial list of the differentially expressed
genes found in the GO category ‘Tube development’ is shown in
Table 3. Taken together, our results show that the gene expression
differences between trachea tumor cells and BM-MSCs were
related to the origin and tumorigenicity of MEi cells.
Genome characterization of MEi cells
To investigate the chromosomal stability and copy number
variations of the post-sorted, expanded MEi cells, karyotyping and
comparative genomic hybridization (CGH) analyses were per-
formed. MEi cells were passaged three times prior to treatment
overnight with Colcemid at 37uC to synchronize the cell cycle to
metaphase. After fixation, cells were stained and 100 metaphase
spreads (50 per sample) underwent karyotype analyses. We found
that the expanded cultures of sorted cells were mostly normal;
46XX but noticed that 9 out of 50 (sample 1); 12 out of 50 (sample
2) counts showed tetraploidy with 85 to 92 chromosomes
(Figure 6c). CGH with an 180K oligo array further revealed
several recurrent benign copy number variations. In addition, a
small duplication of unknown significance was detected on
chromosome X, Xq21.31, ,156 kb (min region chrX:
87,695,049–87,851,109 in hg19). The region did not contain
any known gene and the variant was interpreted as a likely benign
variant. These evaluations confirm that the majority of the
multipotent MEi cells possessed a normal karyotype.
MEi cells did not form teratomas
Teratoma formation assay is commonly used in tumor cell
biology to determine cell potency. We therefore injected MEi cells
Figure 5. In vitro differentiation of MEi (MSC-like mucoepidermoid tumor) cells to endoderm and ectoderm lineages. A representative
image of endoderm differentiation of MEi cells (a–c) and BM-MSCs (d–f) were stained positive for GATA 6, and ectoderm differentiation of MEi cells
(g–i) and BM-MSCs (j–l) were positive for b-III tubulin. Scale bar: 50 mm.
doi:10.1371/journal.pone.0107712.g005
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Figure 6. Gene expression profiles and karyotyping of MEi cells. Two-dimensional cluster plots for the classification of samples based on the
first two principal components. Tumor 1, 2, 3, 4 are MEi cells and MSC 1, 2 are BM-MSCs (a), Each row represents a gene and each column represents a
sample. The expression level of each gene in a single sample is relative to its median abundance across all samples and is depicted according to a
color scale shown on the right. Red and green indicate expression levels respectively above and below the median. (b), a representative image of
tetraploidy and normal karyotype (c) at passage 12+3.
doi:10.1371/journal.pone.0107712.g006
Table 1. KEGG pathways significantly enriched by genes differentially expressed between MEi cells and BM-MSCs.
KEGG Pathway Count % P-Value Fold Enrichment
hsa05200: Pathways in cancer 21 4.95283 1.33E-04 2.566784657
hsa00230: Purine metabolism 12 2.830189 0.001337 3.134784623
hsa04810: Regulation of actin cytoskeleton 14 3.301887 0.002217 2.627037817
hsa04512: ECM-receptor interaction 8 1.886792 0.004564 3.806524184
hsa04510: Focal adhesion 12 2.830189 0.00966 2.422333572
Pathways were identified by DAVID Functional Annotation and ranked by P-value with a cutoff of 0.01. Counts and percentages refer to the number and percentage of
genes from the input list that fit into a given KEGG pathway. Fold enrichment is the magnitude of enrichment for each KEGG pathway compared with the entire gene
list in the Affymetrix Human Gene 1.1 ST Array that serves as the reference.
doi:10.1371/journal.pone.0107712.t001
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(passage 18 at a dose of 26106/animal) into testis or subcutaneous
tissue in severely compromised immunodeficient (SCID-Beige)
mice. Ocular inspection and palpation after eight weeks revealed
no discernible signs of in vivo growth in any of the 6 and 5
animals. Further, microscopical analyses (FISH analysis using a
probe specific for human X/Y chromosomes) were negative;
indicating that MEi cells did not propagate in vivo.
Discussion
‘Adult’ stem cells (or better denoted ‘tissue specific’ stem cells)
are believed to maintain tissue homeostasis during injury but
could, if become dysfunctional also provoke benign or malignant
tumors according to the cancer stem cell paradigm [42]. To date,
tissue specific stem cells have not been demonstrated in
transformed tissues from the human upper respiratory tract.
In the present study, we identified and expanded mesenchymal
stem cell-like (MEi) cells in primary cultures from a rare benign
paediatric mucoepidermoid tracheal tumor. We validated the
tumor origin by immunocytochemistry and revealed high expres-
sion for MUC 1, MAML2 and an absence for smooth muscle actin
[6]. While tetraploidy is not uncommon in healthy subjects, it is
usually not as high as the 20% observed [43]. Furthermore,
balanced translocations are not detected by array CGH. Hence, it
is still plausible that the mucoepidermoid tumor did not include
cross-contamination artifact from mesenchymal cells that migrated
from the healthy tracheal tissue region surrounding the tumor
location.
We report that the self-renewal and differentiation potential of
MEi cells had overlapping properties to normal BM-MSC: (i)
obtaining a nearly homogenous immuno-phenotype displaying
typical MSC characteristics, (ii) lacked in vivo tumor initiation
capacity, (iii) demonstrated fibroblastoid colony forming ability
Table 2. Partial list of differentially expressed genes from the KEGG annotation: Pathways in cancer.
Gene Symbol Gene Name Log2FC adj. P-Value
Hgf hepatocyte growth factor (hepapoietin A; scatter factor) 24.25008 0.000379
Mmp1 matrix metallopeptidase 1 (interstitial collagenase) 24.19169 2.19E-05
PPARG peroxisome proliferator-activated receptor gamma 23.72941 1.02E-05
LAMA4 laminin, alpha 4 23.60148 0.003373
KITLG KIT ligand 23.57558 0.000572
MAPK10 mitogen-activated protein kinase 10 23.00792 0.013107
WNT5A wingless-type MMTV integration site family, member 5A 22.97522 2.19E-05
Ar androgen receptor 22.62261 0.000197
MECOM ecotropic viral integration site 1 22.60297 0.000109
Lama2 laminin, alpha 2 22.26819 0.008147
DAPK2 death-associated protein kinase 2 22.19753 0.000183
cdkn2b cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2.299025 0.000169
TGFB2 transforming growth factor, beta 2 4.278179 3.95E-05
Log2FC is the base 2 logarithm of the fold change, with negative values indicating that the gene is more highly expressed in the tumor samples.
doi:10.1371/journal.pone.0107712.t002
Table 3. Partial list of differentially expressed genes from the Gene Ontology term: Tube development.
Gene Symbol Gene Name Log2FC adj.P.Val
Tcf21 transcription factor 21 25.24902 7.07E-05
tbx5 T-box 5 24.87505 4.59E-06
FOXF1 forkhead box F1 23.75911 4.04E-05
FOXP2 forkhead box P2 22.90287 0.000955
PBX1 pre-B-cell leukemia homeobox 1 22.72587 0.000128
tbx3 T-box 3 22.71177 0.000491
EDNRA endothelin receptor type A 22.1 0.005303
Plxnd1 plexin D1 2.479673 0.000134
RBP4 retinol binding protein 4, plasma 2.808411 3.58E-05
PDGFA platelet-derived growth factor alpha polypeptide 2.861353 0.000571
fgf1 fibroblast growth factor 1 (acidic) 3.334209 0.0053
alx1 ALX homeobox 1 3.370444 4.57E-05
nog noggin 3.516299 1.61E-05
Log2FC is the base 2 logarithm of the fold change, with negative values indicating that the gene is more highly expressed in the tumor samples.
doi:10.1371/journal.pone.0107712.t003
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and (iv) retained mesenchymal tri-lineage differentiation capacity
i.e. osteoblasts, adipocytes and chondrocytes with and without
growth factor induction. In contrast, there were distinct cellular
differences noted between MEi cells and BM-MSCs [44]. The cell
proliferation rates of MEi cells between the early (passage 3) or late
passages (passage 18) were exponentially increasing in cell
numbers.
The gene expression profiling showed however distinct differ-
ences between MEi cells and BM-MSCs with regard to genes
relating to tube development, cell adhesion, angiogenesis, signal
transduction, inflammatory response and regulation of pro-
grammed cell death. Unlike BM-MSCs, the MEi cells did not
show expression of the Androgen receptor when tested by
immunohistochemistry, but more sensitive microarrays found a
4-fold up-regulation of RNA when compared to BM-MSCs.
The initial small size of the tumor biopsy did not easily allow for
analysis of the frequency of MEi cells in the original sample. For
this we instead developed a mathematical model from which we
estimate a frequency of 17.5% MEi cells in the mucoepidermoid
tumor cell mass. Intriguingly, we found the mucoepidermoid
tumor cell mass may possibly contain niche cells (i.e. resident stem
cells/quiescent stem cells). Immunocytochemistry staining of MEi
cells revealed a small sub-population of MEI cells; 12.7%
expressed b-III tubulin (ectodermal marker) and 49.4% expressed
GATA 6 (endodermal marker) were differentiating similarly like
BM-MSCs. Assuming that the niche cells expressed both markers,
the percentage of MEi cells that are niche cells is 6.3%. Given that
17.5% of the tumor cells are MEi cells, the percentage of tumor
cells that are niche cells is therefore 1%.
To our knowledge, the present study is the first report
demonstrating a distinct population of benign human tracheal
tumor cells with stem cell-like properties and warrants further
studies on the role of these cells in initiation, development and/or
progression of this type of tumor of the upper respiratory tract.
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34. Lim ML, Jungebluth P, Sjöqvist S, Nikdin H, Rós K (2013) Decellularized
Feeders: An Optimized Method for Culturing Pluripotent Cells. Stem Cells
Transl Med 2: 975–82.
35. Smyth GK (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:
1544–6115.
36. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
37. Cedervall J, Jamil S, Prasmickaite L, Cheng Y, Eskandarpour M, et al. (2009)
Species-specific in vivo engraftment of the human BL melanoma cell line results
in an invasive dedifferentiated phenotype not present in xenografts. Cancer Res
69: 3746–3754.
Stem Cells in Primary Tracheal Tumors
PLOS ONE | www.plosone.org 11 September 2014 | Volume 9 | Issue 9 | e107712
38. O’Neill ID (2009) t(11;19) translocation and CRTC1-MAML2 fusion oncogene
in mucoepidermoid carcinoma. Oral Oncol 45: 2–9.
39. Auclair PL, Goode RK, Ellis GL (1992) Mucoepidermoid carcinoma of intraoral
salivary glands. Evaluation and application of grading criteria in 143 cases.
Cancer 69: 2021–2030.
40. Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, et al. (2001)
Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with
special reference to histological grading. Am J Surg Pathol 25: 835–845.
41. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review
of sphere-formation as an assay for stem cells. Cell Stem Cell 8: 486–498.
42. Wang Y, Zhang Z, Chi Y, Zhang Q, Xu F, et al. (2013) Long-term cultured
mesenchymal stem cells frequently develop genomic mutations but do not
undergo malignant transformation. 4:e950
43. Annerén G (2008) Increased frequency of tetraploidy in cultured skin fibroblasts
from extremities with reduction malformations. Hereditas 96: 255–259.
44. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, et al. (2007)
Human bone marrow derived mesenchymal stem cells do not undergo
transformation after long-term in vitro culture and do not exhibit telomere
maintenance mechanisms. Cancer Res 67: 9142–9149.
Stem Cells in Primary Tracheal Tumors
PLOS ONE | www.plosone.org 12 September 2014 | Volume 9 | Issue 9 | e107712
